ArticleStem cell research & therapy2018
Human amnion-derived mesenchymal stem cells alleviate lung injury induced by white smoke inhalation in rats.
Article in Stem cell research & therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Effects of mesenchymal stromal cell-conditioned media on measures of lung structure and function: a systematic review and meta-analysis of preclinical studies.Stem cell research & therapy · 2020Pooled it
- Burns: The "Fuse" That Ignites Organ Crisis - A Narrative Review of Mechanisms and Crosstalk in Post-Burn MODS.Journal of inflammation research · 2026Review
- Glucagon Receptor Antagonist for Heart Failure With Preserved Ejection Fraction.Circulation research · 2024Article
- Mesenchymal Stromal Cell-Based Products: Challenges and Clinical Therapeutic Options.International journal of molecular sciences · 2024Review
- Emerging delivery approaches for targeted pulmonary fibrosis treatment.Advanced drug delivery reviews · 2024Review
- Human amnion-derived mesenchymal stem cells attenuate acute lung injury in two different acute lung injury mice models.Frontiers in pharmacology · 2023Article
- Stem cell-based therapy for pulmonary fibrosis.Stem cell research & therapy · 2022Review
- Anthrahydroquinone-2-6-disulfonate is a novel, powerful antidote for paraquat poisoning.Scientific reports · 2021Article
- Stem cells and COVID-19: are the human amniotic cells a new hope for therapies against the SARS-CoV-2 virus?Stem cell research & therapy · 2021Review
- The effects of BMMSC treatment on lung tissue degeneration in elderly macaques.Stem cell research & therapy · 2021Article
- Non-muscle myosin II knockdown improves survival and therapeutic effects of implanted bone marrow-derived mesenchymal stem cells in lipopolysaccharide-induced acute lung injury.Annals of translational medicine · 2021Article
- Characteristics and Therapeutic Potential of Human Amnion-Derived Stem Cells.International journal of molecular sciences · 2021Review
- rhKGF-2 Attenuates Smoke Inhalation Lung Injury of RatsFrontiers in pharmacology · 2021Article
- Expression of heme oxygenase-1 in type II pneumocytes protects against heatstroke-induced lung damage.Cell stress & chaperones · 2021Article
- Mesenchymal stem cells as living anti-inflammatory therapy for COVID-19 related acute respiratory distress syndrome.World journal of stem cells · 2020Review
- Human amniotic mesenchymal stem cells inhibit hepatocellular carcinoma in tumour-bearing mice.Journal of cellular and molecular medicine · 2020Article
- A comparative study of a preclinical survival model of smoke inhalation injury in mice and rats.American journal of physiology. Lung cellular and molecular physiology · 2020Article
- Shen-ling-bai-zhu-san ameliorates inflammation and lung injury by increasing the gut microbiota in the murine model of Streptococcus pneumonia-induced pneumonia.BMC complementary medicine and therapies · 2020Article
- Emerging therapies for smoke inhalation injury: a review.Journal of translational medicine · 2020Review
- Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients with Acute Respiratory Distress Syndrome (ARDS).CellR4-- repair, replacement, regeneration, & reprogramming · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhite smoke inhalation (WSI) is an uncommon but potentially deadly cause of acute lung injury and acute respiratory distress syndrome for which no effective pharmaceutical treatment has been developed. This study aimed to determine the protective effects of human amnion-derived mesenchymal stem cells (hAMSCs) against WSI-induced lung injury in rats.
methodshAMSCs were injected into rats via the tail vein 4 h after WSI. At 1, 3, 7, 14, and 28 days after cell injection, hAMSCs labeled with PKH26 in lung, heart, liver, and kidney tissues were observed by fluorescence microscopy. The lung injury score was determined by hematoxylin and eosin staining. Lung fibrosis was assessed by Masson's trichrome staining. The computed tomography (CT) score was assessed by CT scanning. The wet/dry weight ratio was calculated. The levels of interleukin (IL)-1β, IL-6, and IL-10 were determined by enzyme-linked immunosorbent assays. The expression of surfactant protein (SP)-A, SP-C, and SP-D was measured by Western blotting.
resultsThe injected hAMSCs were primarily distributed in the lung tissues in WSI-induced rats. Compared with the model and phosphate-buffered saline (PBS) group, hAMSC treatment led to reduced lung injury, lung fibrosis, CT score, and inflammation levels in WSI-induced mice. hAMSC treatment also resulted in increased cell retention in the lung, partial pressure of oxygen (PaO
conclusionshAMSCs are a potential cell-based therapy for WSI-induced lung injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.